News related to Orencia (Abatacept) and/or conditions it is approved for
ACR: Abatacept Efficacy in RA Lasts for Two Years (CME/CE)
Source: MedPage Today Rheumatology [2009.10.23]
PHILADELPHIA (MedPage Today) -- Abatacept (Orencia) is effective against clinical symptoms and joint erosion in early rheumatoid arthritis for at least two years, researchers said here.
Judgement In Favour Of NICE On Judicial Review Of Abatacept For Rheumatoid Arthritis Guidance
Source: Arthritis / Rheumatology News From Medical News Today [2009.11.10]
The High Court has ruled in favour of NICE by dismissing the application from Bristol Myers Squibb (BMS), the manufacturer of abatacept, for a judicial review of the NICE guidance on the use of abatacept for the treatment of rheumatoid arthritis. In April 2008, NICE published final guidance which did not recommend abatacept as a treatment option for people with rheumatoid arthritis.
Adeona Announces Publication Of Results Of 160 Patient Phase 2 Clinical Trial Of Oral DnaJP1 For Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2009.11.15]
Adeona Pharmaceuticals, Inc. (AMEX: AEN) announced the publication in the journal Arthritis & Rheumatism of results of a 160-patient, six-month, double-blind, placebo-controlled Phase 2 clinical trial using the company's oral dnaJP1 for the treatment of rheumatoid arthritis (RA). The results of the study were originally presented at the 2008 American College of Rheumatology Annual Meeting. The study was sponsored by the National Institutes of Health (NIH).
How Rheumatoid Arthritis Spreads
Source: MedicineNet Rheumatoid Arthritis Specialty [2009.11.10]
Title: How Rheumatoid Arthritis Spreads
Category: Health News
Created: 11/10/2009 9:50:00 AM
Last Editorial Review: 11/10/2009 9:50:12 AM
Rheumatoid Arthritis Treatment Doesn't Promote Cancer (HealthDay)
Source: Y! Health Arthritis News [2009.10.29]
HealthDay - THURSDAY, Oct. 29 (HealthDay News) -- Treatment with tumor
necrosis factor (TNF) blockers doesn't increase rheumatoid arthritis
patients' risk of cancer, new research has found.
Advancing Personalized Medicine In Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.26]
The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA). RA is the most common type of inflammatory arthritis. Many effective medications exist, but they vary greatly in cost and side effects, and there is no way to predict which drug will work best on an individual. A two-year, $3.
UAB Creates National Network To Advance Personalized Medicine In Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.25]
The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA). RA is the most common type of inflammatory arthritis. Many effective medications exist, but they vary greatly in cost and side effects, and there is no way to predict which drug will work best on an individual. A two-year, $3.
TNF-Alpha Inhibitors Will Continue To Dominate First- And Second-Line Biologic Therapy For The Treatment Of Rheumatoid Arthritis Through 2011
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.23]
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the U
Tocilizumab Shows Sustained Efficacy In Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.23]
PHILADELPHIA - Investigators are reporting that tolicizumab is an effective, long-term treatment option in multiple subgroups of rheumatoid arthritis (RA) patients. These include patients who have an inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR), patients who have an inadequate response to anti-TNF inhibitors (TNF-IR), and patients who have not failed methotrexate.
FDA Approves New Test To Aid In The Diagnosis Of Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.21]
An important assay used to aid in the diagnosis of rheumatoid arthritis (RA) will soon be available on Abbott's ARCHITECT immunoassay analyzers. The FDA has granted 510(k) clearance for an antibody cyclic-citrulinated peptide, or anti-CCP assay, to run on the world class systems. Many patients with RA develop an immune response against proteins containing citrulline long before they present symptoms of the disease.
ACR: Rheumatoid Arthritis Biologics Increase Risk of Skin Cancer (CME/CE)
Source: MedPage Today Dermatology [2009.10.18]
PHILADELPHIA (MedPage Today) -- Rheumatoid arthritis patients being treated with potent tumor necrosis factor inhibitors run an increased risk of developing skin cancer, researchers said here at the American College of Rheumatology's annual meeting.
Chinese Herb May Ease Rheumatoid Arthritis
Source: MedicineNet sulfasalazine Specialty [2009.08.18]
Title: Chinese Herb May Ease Rheumatoid Arthritis
Category: Health News
Created: 8/18/2009
Last Editorial Review: 8/18/2009
Fixing Gums May Help Rheumatoid Arthritis
Source: MedicineNet Gum Disease Specialty [2009.06.15]
Title: Fixing Gums May Help Rheumatoid Arthritis
Category: Health News
Created: 6/15/2009
Last Editorial Review: 6/15/2009
Association Between Rheumatoid Arthritis And Poor Sleep In Women
Source: Compliance News From Medical News Today [2009.06.10]
According to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, symptoms of Rheumatoid Arthritis (RA) negatively affect women's sleep. Sleep is further impaired by pain, depression and poor adherence to RA medications.
Rheumatoid Arthritis
Source: MedicineNet Baker Cyst Specialty [2009.04.08]
Title: Rheumatoid Arthritis
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 4/8/2009
Rheumatoid Arthritis Pictures Slideshow
Source: MedicineNet Baker Cyst Specialty [2008.11.13]
Title: Rheumatoid Arthritis Pictures Slideshow
Category: Slideshows
Created: 11/10/2008
Last Editorial Review: 11/13/2008
Juvenile Arthritis (Juvenile Rheumatoid Arthritis)
Source: MedicineNet anakinra Specialty [2008.03.25]
Title: Juvenile Arthritis (Juvenile Rheumatoid Arthritis)
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 3/25/2008
The impact of smoking and genes on rheumatoid arthritis
Source: The Doctors Lounge - Orthopedics
New insight into the autoimmune triggers for rheumatoid arthritis among smokers with shared epitope genes.
The impact of smoking and genes on rheumatoid arthritis
Source: The Doctors Lounge - Rheumatology
New insight into the autoimmune triggers for rheumatoid arthritis among smokers with shared epitope genes.
Adalimumab plus methotrexate effective for rheumatoid arthritis
Source: The Doctors Lounge - Rheumatology
Adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.
MorphoSys Receives Regulatory Approval To Start Phase 1b/2a Clinical Trial For MOR103 Program
Source: Arthritis / Rheumatology News From Medical News Today [2009.11.09]
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received clearance from Germany's Paul-Ehrlich-Institute as well as a positive opinion from the ethics committees in Germ
Anti-Tumor Necrosis Factor Treatment Does Not Increase Cancer Risk In RA Patients
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.30]
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept.
Link Between Pain Thresholds, Inflammation And Sleep Problems In Arthritis Patients
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.29]
Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. Research published in BioMed Central's open access journal, Arthritis Research & Therapy found that inflammation is associated with heightened pain sensitivity at joint sites, whereas increased sleep problems are associated with heightened pain sensitivity at both joint and non-joint sites.
The Why And The How Of The Benefits Of Fish Oils
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.29]
New research from Queen Mary, University of London and Harvard Medical School has revealed precisely why taking fish oils can help with conditions like rheumatoid arthritis. In a paper published in Nature*, researchers describe how the body converts an ingredient found in fish oils into another chemical called Resolvin D2 and how this chemical reduces the inflammation that leads to a variety of diseases.
No Increased Cancer Risk with Anti-TNF Therapy in RA (CME/CE)
Source: MedPage Today Rheumatology [2009.10.29]
Rheumatoid arthritis (RA) patients receiving anti-tumor necrosis factor (TNF) therapy had no increased risk of cancer during the first six years of treatment compared with biologics-naive patients, a large population-based Swedish study found.
New Clues to How Fish Oils Help Arthritis Patients (HealthDay)
Source: Y! Health Arthritis News [2009.10.28]
HealthDay - WEDNESDAY, Oct. 28 (HealthDay News) -- Researchers think they now
understand the way that fish oils benefit people with rheumatoid arthritis
and other conditions linked to inflammation.
Third PML Case Reported with Rituximab
Source: MedPage Today Rheumatology [2009.10.24]
A case of progressive multifocal leukoencephalopathy has been reported in a rheumatoid arthritis patient taking rituximab (Rituxan) who had not previously received anti-tumor necrosis factor therapy, according to the drug's manufacturer.
ACR: Novel Oral Drug Shows Promise in RA, but No Panacea (CME/CE)
Source: MedPage Today Rheumatology [2009.10.23]
PHILADELPHIA (MedPage Today) -- Six-month data on an investigational oral anti-inflammatory drug confirmed its effectiveness as second-line therapy for rheumatoid arthritis, but it was a bust in patients who had failed biologic therapy, researchers said here.
ACR: Tocilizumab Protects Joints Better than Methotrexate Alone (CME/CE)
Source: MedPage Today Rheumatology [2009.10.23]
PHILADELPHIA (MedPage Today) -- The investigational biologic agent tocilizumab appeared to prevent joint erosion among rheumatoid arthritis patients better than treatment with methotrexate alone, researchers said here.
ACR: Anti-TNF Therapy Better in Refractory RA (CME/CE)
Source: MedPage Today Rheumatology [2009.10.23]
PHILADELPHIA (MedPage Today) -- Joint damage progressed more slowly when rheumatoid arthritis patients who failed initial therapies took biologic agents rather than additional conventional drugs, Swedish researchers said here.
CEL-SCI Presents Data At American College Of Rheumatology Conference Which Suggests That CEL-2000 Has Potential To Slow Damage
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.20]
CEL-SCI Corporation (NYSE Amex: CVM) announced the presentation of new rheumatoid arthritis data at the American College of Rheumatology's annual meeting in Philadelphia, PA. The data, presented by Dr.
FDA: Cancer Warnings Required For TNF Blockers
Source: Irritable-Bowel Syndrome News From Medical News Today [2009.08.18]
The U.S. Food and Drug Administration is requiring stronger warnings in the prescribing information for a class of drugs known as TNF blockers. The warnings, which include an updated boxed warning, highlight the increased risk of cancer in children and adolescents who receive these drugs to treat juvenile rheumatoid arthritis, the inflammatory bowel disorder, Crohn's disease, and other inflammatory diseases.
|
